| Gender Preference | None |
| Age Group | 18 - 99 years |
| Research Start Date | August 31, 2012 |
| Research End Date | February 28, 2014 |
| Principal Investigator | Harold P. Adams, Jr., MD |
| Description |
- Purpose: to determine if a study drug called recombinant tissue plasminogen activator (rt-PA), which dissolves blood clots, can help to improve a patient's condition regarding brain blood clots by rapidly removing the clot from the ventricles when compared to placebo (a fluid that does not dissolve blood clots)
- Eligibility: patients ages 18-80 that are admitted with an intraventricular hemorrhage (bleeding in the ventricles or open spaces inside the brain).
- Duration and Involvement: subjects will receive the study medication while they are hospitalized for their hemorrhage. They will be contacted by phone at 3 and 9 months, and follow up in clinic at 30 days, 6 months, and 1 year (final visit) after enrollment into the study.
|
| Contact Info | Heena Olalde, RN, MSN |
| Keywords | span itemProp='description'>Clear III study ; Neurology ; |